Allergen-specific immunoglobulin E and immunoglobulin G (sIgE and sIgG) (sIgE and sIgG)

Allergen-specific immunoglobulin E (sIgE) and immunoglobulin G (sIgG) are key immunological components that dictate the body's sensitivity or tolerance to environmental antigens (NIH, 2022). sIgE is the primary mediator of Type I hypersensitivity; it binds to high-affinity FcεRI receptors on mast cells and basophils, where allergen-induced cross-linking triggers the release of inflammatory mediators like histamine and leukotrienes (StatPearls, 2023). In contrast, allergen-specific IgG, particularly the IgG4 subclass, acts as a protective "blocking antibody" that competes with IgE for allergen binding, thereby preventing the allergic cascade (PubMed, 2021). Therapeutic strategies targeting these antibodies include the use of monoclonal antibodies like omalizumab, which sequesters free IgE, and allergen immunotherapy (AIT), which aims to induce a shift from IgE-mediated sensitivity to IgG-mediated tolerance (FDA, 2020). These antibodies are central to the pathophysiology of conditions such as allergic asthma, rhinitis, and food allergies (World Allergy Organization, 2021). Monitoring their levels and ratios is essential for clinical diagnosis and for evaluating the success of desensitization treatments (Journal of Allergy and Clinical Immunology, 2020).

Other names

Allergen-specific antibodiesSpecific IgESpecific IgGsIgEsIgGAntigen-specific immunoglobulins

Monoclonal antibodies like omalizumab bind to the Cε3 domain of free IgE, preventing its interaction with FcεRI on mast cells and basophils, which reduces the release of inflammatory mediators (StatPearls, 2023). Allergen immunotherapy (AIT) works by repeatedly exposing the patient to small amounts of allergen to induce "blocking antibodies" of the IgG4 subclass, which compete with IgE for allergen binding and promote immune tolerance (NIH, 2022).